Back to Search
Start Over
A New Subcutaneous Immunoglobulin 20% Formulation (SCIG 20%) with Individualized Infusion Parameters Resulted in a Positive Safety and Tolerability Profile in Patients with PIDD in Europe and North America.
- Source :
- Journal of Allergy & Clinical Immunology; Feb2017 Supplement, Vol. 139, pAB216-AB216, 1p
- Publication Year :
- 2017
Details
- Language :
- English
- ISSN :
- 00916749
- Volume :
- 139
- Database :
- Supplemental Index
- Journal :
- Journal of Allergy & Clinical Immunology
- Publication Type :
- Academic Journal
- Accession number :
- 121130833
- Full Text :
- https://doi.org/10.1016/j.jaci.2016.12.700